Global Benign Prostatic Hyperplasis Devices Market Size, Share, Trends & Growth Analysis Report Segmented By Procedure (Transurethral Resection of the Prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, Laser Surgery, Transurethral Microwave Therapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Prostatic Stenting/Implants, Others), End User , And Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), 2026-2034

Benign Prostatic Hyperplasis Devices Market Size Overview

The global benign prostatic hyperplasis devices market size was valued at USD 10.53 Billion in 2025 and is projected to grow from USD 12.03 Billion in 2026 to USD 34.98 Billion by 2034, at a CAGR of 14.27% during the forecast period. North America dominated the benign prostatic hyperplasis devices market market with a market share of 35.52% in 2025.

The benign prostatic hyperplasia devices is used to diagnose and treat benign prostatic hyperplasia, a non-cancerous enlargement of the prostate gland that affects urinary function in men, particularly those over the age of 50. The market includes minimally invasive surgical instruments, laser therapy systems, implantable devices, resection equipment, and related technologies used across hospitals and specialty urology clinics.

Rising aging male populations and the increasing prevalence of prostate enlargement are steadily strengthening benign prostatic hyperplasia devices market demand. According to the National Institutes of Health, approximately 50% of men aged 51–60 experience symptoms of benign prostatic hyperplasia, while the prevalence increases to nearly 90% among men above 80 years. This widespread occurrence has transformed the treatment landscape over time from open surgeries to minimally invasive procedures supported by advanced medical devices.

Historically, treatment methods were largely limited to surgical prostate removal procedures during the mid-20th century. However, technological advancements in endoscopic equipment, laser therapy, and implantable systems have significantly improved patient outcomes and reduced hospital stay durations. The market has evolved alongside developments in urology, imaging technologies, and precision surgical tools. Government health agencies such as the World Health Organization report that the global population aged 60 years and above surpassed 1 billion in 2023, expanding the long-term patient pool requiring prostate treatments.

Key components of the market include resection systems, laser ablation technologies, microwave therapy devices, implants, and diagnostic support equipment. Increasing healthcare expenditure, expanding urology care infrastructure, and growing awareness of prostate health are contributing to the expansion of the global market across developed and emerging healthcare systems.

Benign Prostatic Hyperplasia Devices Market Trends

The global market is steadily shifting toward minimally invasive and outpatient-based treatment solutions. Healthcare providers increasingly favor device-based procedures that reduce hospital stays, improve patient recovery time, and lower complication rates. According to the U.S. Centers for Disease Control and Prevention, outpatient surgical procedures in the United States have increased by more than 300% since the 1990s, reflecting a broader healthcare trend toward minimally invasive treatment methods. This transition is directly influencing technology adoption within the benign prostatic hyperplasia devices market size as hospitals replace traditional surgical techniques with device-assisted treatments such as laser ablation and implant-based therapies.

Patient behavior is also evolving as awareness of prostate health improves. The American Urological Association reports that more than 3 million office visits related to benign prostatic hyperplasia occur annually in the United States alone. As healthcare systems emphasize early diagnosis and quality-of-life improvements, demand for safer and faster treatment procedures continues to increase. Technological advancements are further reshaping the industry through the development of robotic-assisted surgical systems, advanced laser technologies, and precision imaging tools that enhance surgical accuracy. Digital healthcare integration is another emerging trend, with hospitals increasingly adopting data-guided surgical planning tools and remote monitoring technologies.

Government initiatives aimed at improving men’s health awareness and screening programs are also supporting market expansion. In many countries, national health programs encourage early detection of prostate disorders, indirectly strengthening demand for advanced treatment devices. These developments collectively highlight the market’s movement toward technology-driven, patient-centered urological care.

Benign Prostatic Hyperplasia Devices Market Dynamics

Market Drivers

One of the primary drivers of the global market is the rapid expansion of the global aging male population. Age is the most significant risk factor associated with prostate enlargement. According to the United Nations Department of Economic and Social Affairs, the number of people aged 65 years and older is projected to exceed 1.6 billion by 2050. As men age, the likelihood of developing urinary tract symptoms caused by prostate enlargement rises sharply, creating sustained demand for medical treatment and device-based procedures.

Healthcare statistics from the National Institute of Diabetes and Digestive and Kidney Diseases indicate that benign prostatic hyperplasia accounts for millions of clinical consultations each year. In the United States alone, more than 8 million men receive treatment for the condition annually. Growing awareness campaigns conducted by urological associations and government health agencies are encouraging early diagnosis and treatment, further supporting market expansion.

Another key driver is technological innovation in minimally invasive therapies. Laser-based surgical systems and implantable devices allow urologists to treat prostate enlargement with fewer complications compared with traditional surgeries. According to the American Urological Association, minimally invasive procedures can reduce recovery time by several weeks compared with open surgical interventions. Additionally, healthcare infrastructure improvements across emerging economies are enabling greater access to advanced urology treatments. Rising healthcare spending and expanding hospital networks are creating favorable conditions for the adoption of specialized prostate treatment devices worldwide.

Market Restraints

Despite steady demand growth, the global market faces certain limitations that may restrict broader adoption. One major constraint is the high cost associated with advanced surgical equipment and specialized treatment systems. Laser therapy devices, robotic surgical systems, and implantable technologies often require substantial capital investment by hospitals and specialty clinics. According to the World Health Organization, global healthcare spending surpassed USD 9 trillion in 2022, yet significant disparities remain between high-income and developing healthcare systems. These disparities limit the availability of advanced treatment devices in resource-constrained regions.

Limited awareness and delayed diagnosis of prostate conditions also contribute to market restraints. In several developing countries, men often seek treatment only after symptoms become severe, reducing the opportunity for early intervention through minimally invasive device-based procedures. Data from the International Continence Society indicates that lower urinary tract symptoms associated with benign prostatic hyperplasia remain underreported in many populations due to stigma and lack of routine screening.

Regulatory approval requirements and clinical validation processes represent another barrier to market expansion. Medical devices used in urological surgery must undergo extensive testing to ensure patient safety and effectiveness. Regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency enforce strict compliance standards, which can lengthen product development timelines. These factors collectively create challenges for new market entrants and may slow the pace of benign prostatic hyperplasia devices market size in certain healthcare systems.

Market Opportunities

The global market presents multiple opportunities driven by healthcare modernization and technological innovation. Increasing adoption of minimally invasive surgical procedures is opening new growth avenues for device manufacturers. Healthcare providers increasingly prioritize treatments that minimize hospitalization time and reduce postoperative complications. According to the World Health Organization, surgical procedures performed globally exceed 300 million annually, and minimally invasive technologies account for a growing portion of these treatments.

Expansion of healthcare infrastructure in emerging economies represents another major opportunity. Governments in Asia, Latin America, and parts of Africa are investing heavily in hospital construction and medical equipment upgrades. The World Bank reports that global healthcare infrastructure investments have increased steadily over the past decade as countries strengthen their medical systems. These improvements create favorable conditions for the adoption of advanced urology devices and treatment systems.

Technological advancements also provide opportunities for market expansion. Innovations such as robotic-assisted urological surgery, high-precision laser systems, and implantable treatment devices are improving clinical outcomes and patient comfort. These innovations allow healthcare providers to offer safer and faster treatments for prostate enlargement. Additionally, increasing collaboration between medical device companies and research institutions is accelerating the development of next-generation treatment technologies. As healthcare systems continue to prioritize patient-centered care and early disease management, demand for advanced prostate treatment devices is expected to increase significantly.

Market Challenges

The global market faces several operational and technological challenges that influence industry dynamics. One of the key challenges is the complexity associated with device training and clinical adoption. Advanced surgical equipment such as laser therapy systems and robotic surgical platforms require specialized training for urologists and surgical teams. According to the World Health Organization, shortages of skilled healthcare professionals remain a major concern, particularly in developing healthcare systems where access to advanced medical training programs is limited.

Another challenge involves reimbursement policies and healthcare funding structures. Insurance coverage and reimbursement guidelines vary significantly across countries, affecting the affordability of advanced treatment procedures. Government healthcare agencies and insurance providers often require strong clinical evidence before approving coverage for new medical technologies. These regulatory and reimbursement complexities can slow the adoption of innovative devices within hospitals and specialty clinics.

Supply chain disruptions and medical equipment manufacturing constraints also present ongoing challenges. The global healthcare industry experienced significant disruptions during the COVID-19 pandemic, highlighting vulnerabilities in medical device supply chains. According to the World Trade Organization, international medical equipment trade faced major logistical challenges during recent global crises, impacting product availability and distribution timelines. Addressing these challenges will require improved supply chain resilience, expanded clinical training programs, and supportive healthcare policies to sustain long-term benign prostatic hyperplasia devices market share development.

Impact of War, Trade Protectionism, and Artificial Intelligence

Recent geopolitical tensions and evolving trade policies have influenced the global medical device industry, including the benign prostatic hyperplasia devices market. Trade protectionism and tariffs on medical equipment components have affected international supply chains, increasing production costs for device manufacturers. According to the World Trade Organization, trade restrictions on medical technologies increased during recent geopolitical conflicts, impacting cross-border distribution of healthcare equipment.

At the same time, artificial intelligence is emerging as a transformative force in urological healthcare. AI-driven diagnostic tools and surgical planning software are improving precision in prostate treatment procedures. Government-funded digital health programs in countries such as the United States, Germany, and Japan are encouraging the integration of AI technologies into medical systems. These tools help physicians analyze patient data, predict treatment outcomes, and optimize surgical procedures. As AI adoption expands across healthcare systems, the benign prostatic hyperplasia devices market size is expected to benefit from improved clinical efficiency and innovation in urological treatment technologies.

Contact Us

Benign Prostatic Hyperplasia Devices Market Segmentation Insights

Benign Prostatic Hyperplasia Devices Market Analysis, By Procedure

By procedure, the market is categorized into transurethral resection of the prostate (TURP), prostatic urethral lift (PUL), prostatectomy, laser surgery, transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA), prostatic stenting/implants, and others.

• The largest segment in the market is transurethral resection of the prostate (TURP), which accounted for 26.68% of the total share in 2025. TURP remains the most widely used procedure because it is considered the clinical gold standard for treating moderate to severe prostate enlargement. Hospitals and urology centers frequently perform this procedure because it offers reliable symptom relief and strong long-term outcomes for patients. According to the American Urological Association, TURP continues to be recommended for patients who do not respond to medication therapy. The availability of advanced endoscopic resection equipment and improved surgical imaging systems has strengthened the adoption of this procedure.
• The fastest growing segment is prostatic urethral lift (PUL). This treatment method is gaining popularity because it is minimally invasive and preserves normal prostate tissue while improving urinary flow. Increasing patient preference for procedures that avoid extensive surgery and reduce recovery time is accelerating adoption. According to clinical reports from the National Institutes of Health, minimally invasive treatments are becoming more common due to reduced complication risks and faster patient recovery. The PUL procedure typically allows patients to return home on the same day, which improves hospital efficiency and patient convenience. Growing awareness among patients and physicians about these benefits is encouraging adoption across hospitals and specialized urology centers. These advantages are supporting rapid market growth within this segment.

Benign Prostatic Hyperplasia Devices Market Analysis, By End User

By end user, the market is categorized into hospitals and clinics, ambulatory surgical centres, and others.

• The hospitals and clinics segment led the market with 66.65% of the total share in 2025. Hospitals remain the primary treatment centers for prostate enlargement because they possess the necessary surgical infrastructure, specialized urology departments, and trained healthcare professionals required for advanced treatment procedures. Government healthcare systems and private hospitals frequently invest in specialized surgical equipment, enabling them to perform a wide range of prostate treatment procedures including laser therapy, implant procedures, and resection surgeries. According to the World Health Organization, hospitals account for the majority of surgical procedures performed globally due to their ability to provide multidisciplinary care and emergency support. The presence of advanced diagnostic imaging, anesthesia facilities, and postoperative care units further strengthens the dominance of hospitals within the benign prostatic hyperplasia devices market share landscape.
• The fastest growing segment is ambulatory surgical centres. These facilities are gaining traction because they provide cost-effective outpatient treatment options for minimally invasive procedures. Advances in surgical technology and anesthesia techniques allow many prostate treatments to be performed without requiring extended hospital stays. Healthcare policies in several countries are also encouraging the use of outpatient surgical centers to reduce hospital congestion and healthcare costs. According to healthcare statistics from the U.S. Centers for Medicare & Medicaid Services, the number of outpatient surgical procedures has increased steadily as healthcare systems emphasize efficiency and patient convenience. These trends are contributing to rising benign prostatic hyperplasia devices market growth in the ambulatory surgical center segment.

Benign Prostatic Hyperplasia Devices Market Regional Insights

North America

North America held the largest share of 35.52% of the global benign prostatic hyperplasia devices market in 2025, supported by strong healthcare infrastructure and high diagnosis rates of prostate disorders among aging men. The U.S. benign prostatic hyperplasia devices market accounted for 5.65% in 2025, reflecting high adoption of minimally invasive procedures such as laser surgery and transurethral therapies. According to the U.S. National Institutes of Health, nearly 50% of men aged 50–60 experience symptoms related to benign prostatic hyperplasia, which directly increases procedure volumes in hospitals and specialized urology centers. Canada also contributes to regional expansion, supported by increasing access to advanced urological care and government investment in surgical infrastructure.

The region also benefits from strong clinical adoption of innovative technologies including robotic-assisted procedures and laser-based therapies. The American Urological Association reports that millions of BPH-related procedures are performed annually in North America, with hospitals being the primary treatment centers due to the need for advanced surgical equipment. High healthcare spending, early diagnosis programs, and continuous medical technology innovation continue to support market demand across the region.

Europe

Europe represents a well-established healthcare market with strong adoption of advanced urological treatment technologies. The United Kingdom benign prostatic hyperplasia devices market held a market share of 5.35% in 2025, driven by the growing aging male population and expanding public healthcare coverage for urology treatments. Government healthcare statistics in the UK indicate that over 3 million men are estimated to suffer from lower urinary tract symptoms related to prostate enlargement, creating consistent demand for BPH devices. Similarly, the France benign prostatic hyperplasia devices market accounted for 4.95% of the global share in 2025, supported by high hospital procedure volumes and increasing use of laser-based surgical solutions.

Germany, the UK, and France remain key contributors to regional demand due to advanced medical infrastructure and strong reimbursement frameworks for urological procedures. In Southern Europe, the Italy benign prostatic hyperplasia devices market held a 2.05% share in 2025, supported by increased adoption of minimally invasive treatments. The European Association of Urology notes that BPH affects nearly 30 million men across Europe, highlighting the growing healthcare burden and the need for improved surgical treatment technologies. Continuous investments in healthcare modernization and growing awareness programs are expected to sustain long-term benign prostatic hyperplasia devices market growth across the region.

Asia Pacific

The Asia Pacific region is experiencing rapid expansion in the B benign prostatic hyperplasia devices market t due to increasing healthcare access and the rising aging male population. The Japan benign prostatic hyperplasia devices market is expected to record healthy growth over the forecast timeline, supported by advanced healthcare technology adoption and one of the world’s oldest populations. According to Japan’s Ministry of Health, more than 28% of the country’s population is above the age of 65, which significantly increases the prevalence of prostate disorders requiring medical intervention.

Countries such as China, India, Japan, and South Korea are expanding healthcare infrastructure and investing in urology treatment centers to address rising patient demand. Government health statistics in China indicate that over 100 million men are estimated to experience lower urinary tract symptoms associated with prostate enlargement, creating large procedural demand. India is also witnessing increased adoption of minimally invasive urological procedures in urban hospitals as healthcare spending rises. Expanding medical tourism, improving hospital infrastructure, and rising awareness of prostate health are collectively strengthening benign prostatic hyperplasia devices market demand in the Asia Pacific region.

Latin America

The Latin America benign prostatic hyperplasia devices market is gradually expanding due to improving healthcare infrastructure and increasing diagnosis rates of prostate disorders. Brazil leads the region due to its large healthcare network and growing adoption of advanced surgical technologies for urology treatments. Public healthcare programs and private hospital investments are increasing access to minimally invasive BPH procedures. According to regional health statistics, prostate enlargement symptoms affect nearly 40% of men over the age of 50 in Latin America, creating a growing demand for treatment solutions.

Countries including Brazil, Argentina, and Chile are focusing on improving urology care services through hospital modernization programs and medical training initiatives. Brazil’s healthcare authorities have also increased investments in specialized surgical equipment to improve patient outcomes in urological procedures. Although the region currently accounts for a smaller portion of global procedure volumes compared to North America and Europe, increasing awareness campaigns related to men’s health and improved diagnostic screening are expected to support steady benign prostatic hyperplasia devices market growth.

Middle East & Africa

The Middle East & Africa benign prostatic hyperplasia devices market is developing as healthcare systems across the region expand their surgical capabilities and specialist care facilities. Countries such as Saudi Arabia and South Africa are investing heavily in healthcare modernization to improve treatment access for chronic diseases including urological disorders. According to regional health reports, the prevalence of prostate enlargement increases sharply after age 50, affecting nearly half of men in that age group, which is creating increasing procedural demand in hospitals.

Saudi Arabia’s national healthcare transformation programs are expanding hospital capacity and adopting advanced surgical technologies including laser-based prostate surgery. South Africa is also strengthening its healthcare infrastructure through public-private partnerships aimed at improving specialized surgical services. While awareness and diagnostic rates are still developing in several parts of the region, improving healthcare investment and rising life expectancy are expected to gradually increase benign prostatic hyperplasia devices market share in the Middle East & Africa.

Benign Prostatic Hyperplasia Devices Market Competitive Overview

The global market is moderately competitive, with a mix of established multinational medical technology companies and specialized urology device manufacturers. Large global companies dominate advanced surgical technologies such as laser systems, robotic surgical tools, and minimally invasive implants, while emerging players focus on innovative treatment solutions for outpatient procedures.

Industry participants are investing heavily in research and development to improve procedural efficiency, reduce surgical complications, and shorten patient recovery time. According to the World Health Organization, prostate disorders affect hundreds of millions of men globally, creating long-term demand for effective treatment technologies. Companies are also expanding collaborations with hospitals, research institutions, and healthcare organizations to develop advanced minimally invasive surgical systems. Strategic product launches, clinical trials, and partnerships with urology associations are commonly used approaches to strengthen benign prostatic hyperplasia devices market demand and expand global market presence.

Leading Market Players in the Benign Prostatic Hyperplasia Devices Market

• Olympus Corporation: Olympus Corporation is a global medical technology company known for its strong presence in endoscopy and minimally invasive surgical devices used in urology procedures. The company develops advanced visualization systems and surgical instruments that support treatments such as transurethral resection and laser-based prostate procedures. Olympus focuses on improving procedural precision and patient outcomes through continuous technological innovation. The company collaborates with hospitals and urology specialists worldwide to enhance the effectiveness of minimally invasive treatments. With its strong global distribution network and clinical training initiatives, Olympus plays an important role in expanding access to advanced prostate treatment solutions across healthcare systems.
• Boston Scientific Corporation: Boston Scientific Corporation is a major developer of minimally invasive medical devices used in urology and other specialized healthcare fields. The company has introduced several innovative technologies designed to treat prostate enlargement with less invasive approaches, helping reduce hospital stays and recovery times for patients. Boston Scientific works closely with healthcare providers and urology specialists to develop devices that improve treatment outcomes while minimizing procedural complications. The company also invests heavily in clinical research and product development to address growing demand for effective BPH treatments. Its strong global presence and continuous innovation have made it one of the key contributors to advancements in prostate treatment technologies.
• Teleflex Incorporated: Teleflex Incorporated is a diversified medical technology company that develops and manufactures devices used in critical care, surgical procedures, and urology treatments. The company offers specialized instruments and minimally invasive solutions designed to support procedures used for treating benign prostatic hyperplasia. Teleflex emphasizes product innovation, physician training programs, and global distribution to expand access to advanced treatment technologies. Through collaborations with hospitals and healthcare organizations, the company aims to improve surgical outcomes and reduce procedural complexity. Teleflex’s continued focus on developing innovative urology solutions helps strengthen its presence within the global market.

Top Strategies Followed by Players

• Focus on minimally invasive treatment innovation: Medical device manufacturers in the market are increasingly prioritizing the development of minimally invasive surgical technologies. Companies are investing in advanced laser-based systems, robotic surgical tools, and implantable devices designed to reduce complications and shorten recovery periods. According to urology associations, minimally invasive procedures have significantly improved patient outcomes by reducing hospitalization time and lowering surgical risks. As healthcare providers shift toward outpatient procedures and patient-friendly treatments, manufacturers are focusing on designing devices that deliver efficient treatment with minimal tissue damage. Continuous research and clinical testing allow companies to introduce new technologies that enhance surgical precision and procedural safety.
• Strategic collaborations with hospitals and research institutions: Leading companies in the benign prostatic hyperplasia devices market frequently collaborate with hospitals, academic institutions, and urology associations to accelerate product development and clinical adoption. These partnerships enable manufacturers to conduct clinical trials, validate device performance, and gain regulatory approvals for new technologies. Collaborative programs also help companies understand evolving clinical requirements and improve product design based on physician feedback. Healthcare institutions benefit from access to advanced surgical tools and training programs that improve treatment capabilities. Such collaborations support technology advancement and allow companies to expand their market presence while strengthening relationships with healthcare providers.
• Expansion through product portfolio diversification: Companies are expanding their product portfolios to address multiple treatment approaches for benign prostatic hyperplasia. This includes devices used in procedures such as transurethral resection, laser surgery, prostatic urethral lift, and implant-based therapies. By offering a wide range of solutions, manufacturers can meet the diverse needs of healthcare providers and patients across different healthcare settings. Portfolio diversification also allows companies to respond to evolving clinical practices and growing demand for advanced treatment technologies. Through continuous innovation and expansion of device offerings, industry players aim to strengthen their competitive position and improve access to effective prostate treatment solutions worldwide.

List of Companies Profiled in the Report are:

• Karl Storz SE & Co. KG
• OmniGuide Holdings Inc.
• Olympus Corporation
• Richard Wolf GmbH
• Lumenis Ltd.
• Urologix LLC
• Boston Scientific Corporation
• Coloplast Corp.
• Medifocus Inc.
• biolitec AG
• Teleflex Incorporated
• Urotech Medical Inc.
• Becton Dickinson and Company
• Procept BioRobotics Corporation

Benign Prostatic Hyperplasia Devices Market Recent Developments

Mar 2026: PROCEPT BioRobotics announced the international launch of the HYDROS® Robotic System, starting in the UK to expand global access to Aquablation therapy for benign prostatic hyperplasia (BPH). The AI-enabled robotic platform integrates real-time ultrasound imaging and robotic treatment planning to remove obstructive prostate tissue precisely. The company plans further geographic expansion across additional international markets in 2026 to increase adoption of minimally invasive robotic BPH procedures.

Jan 2026: Butterfly Medical announced the completion of a pivotal clinical trial evaluating its minimally invasive device for treating benign prostatic hyperplasia. The study demonstrated the device’s potential effectiveness in relieving urinary symptoms caused by prostate enlargement, and the company plans to present detailed clinical outcomes at the American Urological Association (AUA) 2025 meeting to support further regulatory and commercialization steps.

Dec 2025: ProVerum Medical Ltd. received U.S. FDA approval for the ProVee System, a next-generation prostatic urethral stent designed to treat patients with benign prostatic hyperplasia. The device gently opens the obstructed prostate without cutting or burning tissue and aims to reduce lower urinary tract symptoms while offering faster recovery compared to conventional surgical procedures.

Global Benign Prostatic Hyperplasis Devices Market Report Scope and Key Segmentation

List of Segments Covered

This section of the market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Procedure

• Transurethral Resection of the Prostate (TURP)
• Prostatic Urethral Lift (PUL)
• Prostatectomy
• Laser Surgery
• Transurethral Microwave Therapy (TUMT)
• Transurethral Needle Ablation of the Prostate (TUNA)
• Prostatic Stenting/Implants
• Others

By End User

• Hospitals and Clinics
• Ambulatory Surgical Centres
• Others